These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Intravenous immunoglobulin for Guillain-Barré syndrome. Hughes RA; Swan AV; van Doorn PA Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327 [TBL] [Abstract][Full Text] [Related]
23. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry. Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437 [TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Beauté J; Levy P; Millet V; Debré M; Dudoit Y; Le Mignot L; Tajahmady A; Thomas C; Suarez F; Pellier I; Hermine O; Aladjidi N; Mahlaoui N; Fischer A; Clin Exp Immunol; 2010 May; 160(2):240-5. PubMed ID: 20041884 [TBL] [Abstract][Full Text] [Related]
26. Managing cost of care and healthcare utilization in patients using immunoglobulin agents. Vaughan LJ Am J Manag Care; 2019 Jun; 25(6 Suppl):S105-S111. PubMed ID: 31318516 [TBL] [Abstract][Full Text] [Related]
28. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Kallenberg CG Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584 [TBL] [Abstract][Full Text] [Related]
29. Audit of provincial IVIG Request Forms and efficacy documentation in four Ontario tertiary care centres. Shih AW; Jamula E; Diep C; Lin Y; Armali C; Heddle NM; Traore A; Doherty J; Shah N; Hillis CM Transfus Med; 2017 Apr; 27(2):122-131. PubMed ID: 28144996 [TBL] [Abstract][Full Text] [Related]
30. Use of Polyclonal Intravenous Immunoglobulin at a Paediatric Referral Hospital in South Africa Between 2009 and 2012. Raiman S; Knight SE; Eley B; Welzel TB J Clin Immunol; 2015 Oct; 35(7):668-74. PubMed ID: 26369911 [TBL] [Abstract][Full Text] [Related]
31. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy. Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353 [TBL] [Abstract][Full Text] [Related]
32. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. Alsina L; Montoro JB; Moral PM; Neth O; Pica MO; Sánchez-Ramón S; Presa M; Oyagüez I; Casado MÁ; González-Granado LI Eur J Health Econ; 2022 Apr; 23(3):551-558. PubMed ID: 34546485 [TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Alejandria MM; Lansang MA; Dans LF; Mantaring JB Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD001090. PubMed ID: 24043371 [TBL] [Abstract][Full Text] [Related]
34. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. Giannini EH; Lovell DJ; Silverman ED; Sundel RP; Tague BL; Ruperto N J Rheumatol; 1996 May; 23(5):919-24. PubMed ID: 8724309 [TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Ohlsson A; Lacy JB Cochrane Database Syst Rev; 2004; (1):CD001239. PubMed ID: 14973965 [TBL] [Abstract][Full Text] [Related]
36. Unified infusion rates for 10% intravenous immunoglobulin. Crispin P; Burgess M; Beath A Transfus Apher Sci; 2018 Apr; 57(2):243-246. PubMed ID: 29530406 [TBL] [Abstract][Full Text] [Related]
37. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin for Guillain-Barré syndrome. Hughes RA; Swan AV; van Doorn PA Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476 [TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Ohlsson A; Lacy JB Cochrane Database Syst Rev; 2001; (2):CD001239. PubMed ID: 11405981 [TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Dobloug C; Walle-Hansen R; Gran JT; Molberg Ø Clin Exp Rheumatol; 2012; 30(6):838-42. PubMed ID: 22935197 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]